Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease.
A framework is presented that distinguishes the conceptually separate decisions of which treatment strategy is optimal from the question of whether more information is required to inform this choice in the future. The authors argue that the choice of treatment strategy should be based on expected utility, and the only valid reason to characterize the uncertainty surrounding outcomes of interest is to establish the value of acquiring additional information. A Bayesian decision theoretic approach is demonstrated through a probabilistic analysis of a published policy model of Alzheimer's disease. The expected value of perfect information is estimated for the decision to adopt a new pharmaceutical for the population of patients with Alzheimer's disease in the United States. This provides an upper bound on the value of additional research. The value of information is also estimated for each of the model inputs. This analysis can focus future research by identifying those parameters where more precise estimates would be most valuable and indicating whether an experimental design would be required. We also discuss how this type of analysis can also be used to design experimental research efficiently (identifying optimal sample size and optimal sample allocation) based on the marginal cost and marginal benefit of sample information. Value-of-information analysis can provide a measure of the expected payoff from proposed research, which can be used to set priorities in research and development. It can also inform an efficient regulatory framework for new healthcare technologies: an analysis of the value of information would define when a claim for a new technology should be deemed substantiated and when evidence should be considered competent and reliable when it is not cost-effective to gather any more information.
Claxton
K
K
University of York.
Neumann
P J
PJ
Araki
S
S
Weinstein
M C
MC
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000191:economics; D001499:Bayes Theorem; D003362:Cost-Benefit Analysis; D003662:Decision Theory; D018450:Disease Progression; D000077265:Donepezil; D006801:Humans; D007189:Indans / Q000191:economics / Q000627:therapeutic use*; D016247:Information Storage and Retrieval / Q000191:economics; D018697:Nootropic Agents / Q000191:economics / Q000627:therapeutic use*; D010880:Piperidines / Q000191:economics / Q000627:therapeutic use*; D011050:Policy Making; D013673:Technology Assessment, Biomedical / Q000191:economics*; D016896:Treatment Outcome; D014481:United States; D026712:Value of Life
D007189:Indans; D018697:Nootropic Agents; D010880:Piperidines; D000077265:Donepezil